Phase II study of perioperative mFOLFOX plus Panitumumab for stage III rectal cancer

Phase II study of perioperative mFOLFOX plus Panitumumab for stage III rectal cancer - perioperative mFOLFOX plus Panitumumab for stage III rectal cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006039

Enrollment

Registered

2011-07-26

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

anticancer drags (mFOLFOX6 plus panitumumab)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinically staged T3 N1-2 rectal cancer patients were enrolled in this study.

Exclusion criteria

Exclusion criteria: Previous treatment of rectal cancer Multiple cancer and/or double cancer Any severe concurrent medical condition which would make it undesirable

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactMitsuyoshi Ota

Yokohama City University Gastroenterological Surgery

m_ota@yokohama-cu.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026